行情

CMRX

CMRX

Chimerix
NASDAQ

实时行情|Nasdaq Last Sale

1.340
-0.120
-8.22%
盘后: 1.390 +0.05 +3.73% 16:14 10/22 EDT
开盘
1.470
昨收
1.460
最高
1.510
最低
1.330
成交量
222.16万
成交额
--
52周最高
4.400
52周最低
1.330
市值
8,210.22万
市盈率(TTM)
-1.0141
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CMRX 新闻

  • 沪指小幅震荡 约翰逊月底“脱欧”计划落空
  • 新浪财经.38分钟前
  • 耐克任命前EBay高管为下任CEO 加强电商战略
  • 新浪财经.39分钟前
  • IMF:下调2019年和2020年亚洲经济增速预期
  • 新浪财经.56分钟前
  • 美财长称发行天秤币尚不成熟 扎克伯格将出席听证会
  • 澎湃新闻.1小时前

更多

所属板块

生物技术和医学研究
+0.44%
制药与医学研究
+0.60%

热门股票

名称
价格
涨跌幅

CMRX 简况

Chimerix, Inc. is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses. It is also advancing the development of CMX521 for the treatment and prevention of norovirus. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available. Brincidofovir is an investigational oral nucleotide analog that has shown spectrum antiviral activity against all five families of double-stranded deoxyribonucleic acid (dsDNA) viruses that affect humans. Oral and IV formulations of brincidofovir are in development, both of which deliver the active antiviral directly to the site of viral replication.
展开

Webull提供Chimerix Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。